A Phase I, Randomized, Open-label, Single-dose, Four-period, Four-treatment, Cross-over Study to Assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants

This study aim to assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants.

Start Date05 Dec 2024

Sponsor / Collaborator

AstraZeneca PLC

[+1]

NCT06269484

/ CompletedPhase 2

A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy, Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants With Cirrhosis

This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin and zibotentan monotherapy as compared to placebo in patients with cirrhosis.

Start Date15 Feb 2024

Sponsor / Collaborator

AstraZeneca PLC

NCT05516498

/ TerminatedPhase 2

A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension

This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.

Start Date31 Oct 2022

Sponsor / Collaborator

AstraZeneca PLC

100 Clinical Results associated with Zibotentan

100 Translational Medicine associated with Zibotentan

100 Patents (Medical) associated with Zibotentan

115

Literatures (Medical) associated with Zibotentan

01 Jul 2026·AMERICAN HEART JOURNAL

Exercise treadmill testing for efficacy evaluation in randomized, controlled trials

Article

Author: Kaski, Juan Carlos ; Welsh, Paul ; Padmanabhan, Sandosh ; Galasko, Gavin ; Oliveira, Joana Maria Gomes ; Ambery, Philip ; Arnold, Jayanth Ranjit ; McConnachie, Alex ; Al-Lamee, Rasha ; Morrow, Andrew ; Ford, Thomas J ; Hoole, Stephen ; Clesham, Gerald ; Abraham, George R ; Weir, Robin A ; Perera, Divaka ; Berry, Colin ; Ferreira, Vanessa ; Spyridopoulos, Ioakim ; Sinha, Aish ; Sattar, Naveed ; Rakhit, Roby ; Kotecha, Ashish ; Greenwood, John P ; Young, Robin ; Davenport, Anthony

Exercise treadmill testing measures functional capacity and inducible myocardial ischemia and has historically served as an endpoint in phase 2 trials. The Precision Medicine with Zibotentan in Microvascular Angina trial evaluated the selective endothelin-A receptor antagonist zibotentan as a potential disease-modifying therapy for microvascular angina. The trial had a randomized, double-blind, cross-over design and the primary outcome was exercise duration. Compared with placebo, zibotentan at a dose of 10-mg daily for 12-weeks did not improve exercise duration or angina symptoms. In this prespecified analysis, exercise duration was compared across four sequential study visits and the factors associated with within-trial changes were evaluated. Exercise test duration increased progressively in all participants during sequential trial phases, independent of treatment with either zibotentan or placebo. This improvement in exercise duration was associated with female sex (interaction p-value = .0213; effect estimate [95% confidence interval]) 34.95 [13.99, 55.78] seconds, P = .002). In conclusion, the exercise test has limitations as an objective endpoint of efficacy in randomized trials. PRIZE; https://clinicaltrials.gov/study/NCT04097314 Clinicaltrials.gov Registration: NCT04097314.

01 Nov 2025·BIOORGANIC CHEMISTRY

The emerging role of Oxadiazole derivatives as VEGFR and EGFR inhibitors in Cancer therapy

Review

Author: Nath, Rajarshi ; Akhtar, Md Jawaid ; Chakraborty, Anhic ; Debnath, Biplab ; Khan, Shah Alam ; Maity, Arindam

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) play a key role in cell proliferation, angiogenesis, and cell migration. Both pathways are recognised as key mediators of tumor angiogenesis and metastasis. Drugs that target multiple cellular pathways are generally more effective than those that inhibit a single pathway. The cumulative research over the past several decades has led to the development of many drugs effective against EGFR and VEGFR, but the complexity of the tumors resulted in the emergence of resistance to monotherapy with either EGFR or VEGFR inhibitors. Available evidence suggests that inhibition of both EGFR and VEGFR can overcome the tumor resistance and will significantly improve the clinical outcomes. Notably, oxadiazole derivatives have been shown to demonstrate greater tumor growth inhibition by targeting both EGFR and VEGFR pathways compared with standard treatments. Oxadiazoles are bio-isosteres of amides and esters that contribute to hydrogen bond formation within the receptors and enhance the anticancer activity. For example, drug zibotentan, an oxadiazole ring-containing drug present in phase III clinical trials, has shown anticancer effects by slowing down cancer progression and improving survival rates in some patients. This review article highlights the importance of dual EGFR and VEGFR pathway inhibition, summarizes common methods for synthesizing oxadiazole ring derivatives, and discusses the VEGFR and EGFR inhibitory potential of oxadiazole derivatives reported between 2019 and 2025. The structure-activity relationship (SAR) studies and docking insights presented in this article could help medicinal chemists in designing and developing next-generation VEGFR and EGFR inhibitors.

01 Oct 2025·Medicinal Chemistry

A Comprehensive Review: Synthesis and Pharmacological Activities of 1,3,4-Oxadiazole Hybrid Scaffolds

Review

Author: Pandit, Amit ; Lata, Suman ; Choudhary, Lucky ; Abbot, Vikrant ; Bharwal, Ankita

Introduction::

Heterocyclic derivatives, particularly those containing heteroatoms such as oxygen and nitrogen, represent a significant portion of currently marketed drugs. Among these, the aromatic heterocycle 1,3,4-oxadiazole, characterized by an N=C=O-linkage, stands out due to its remarkable biological activities. These activities include anti-inflammatory, anti-cancer, antioxidant, anti-tubercular, antiviral, anti-diabetic, and antibacterial effects. Notably, several commercially available medications, such as tiodazosin, raltegravir, zibotentan, and nesapidil, incorporate this structural motif.

Methods::

This review compiles and analyzes existing synthetic methods for preparing 1,3,4- oxadiazole and its derivatives. By examining various synthetic routes and methodologies, the review provides a detailed overview of the strategies employed to generate these biologically active compounds.

Results::

The review highlights the potential of 1,3,4-oxadiazole derivatives in addressing the toxicity, side effects, and drug resistance commonly associated with existing anticancer therapies. By combining the 1,3,4-oxadiazole moiety with other heteroatoms, novel hybrid derivatives have been synthesized, demonstrating enhanced pharmacological activities across various therapeutic areas.

Conclusion::

This comprehensive review offers valuable insights into the synthesis and pharmacological applications of 1,3,4-oxadiazoles. It serves as a crucial resource for researchers exploring the development of new therapeutic compounds, with the ultimate goal of improving public health. The review builds on existing literature from the last two decades to present an exhaustive examination of the potential of 1,3,4-oxadiazole derivatives in drug development.

News (Medical) associated with Zibotentan

26 Jun 2024

·www.fiercepharma.com

New CKD drugs are promising, but need stronger efficacy data, kidney docs say: GlobalData

In total, the chronic kidney disease market is forecast to balloon in size from $2.2 billion last year to $13.5 billion by 2033, during which time a range of new treatments are on track to make their debuts. Though a host of drugs currently under development are poised to massively expand the existing market for chronic kidney disease (CKD) treatments, they’ll need to go further to win the support of doctors, according to a new report. The segment is expected to expand at a compound annual growth rate of nearly 20% over the course of a decade, according to GlobalData’s estimates. The report comprises the seven major markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan, though GlobalData noted that the U.S. will be a disproportionately large contributor to that growth, thanks to its higher prevalence of CKD and costs of prescription medications. In total, the CKD market is forecast to balloon in size from $2.2 billion last year to $13.5 billion by 2033, during which time a range of new treatments are on track to make their debuts. Among those now in development are ProKidney’s cell therapy rilparencel, also known as React, and AstraZeneca’s combinations of zibotentan and dapagliflozin, and balcinrenone and dapagliflozin—all of which are currently in clinical trials. Meanwhile, Novo Nordisk is also exploring a potential expanded indication for Ozempic in CKD. Just last month, Novo shared results from its FLOW study of once-weekly Ozempic’s ability to reduce the risk of major kidney disease events in patients with both CKD and Type 2 diabetes. With a median follow-up period of nearly three and a half years, the study found that participants treated with the GLP-1 had an average 24% risk reduction compared to those assigned to the placebo group, and their rate of kidney function decline was “significantly slower.” Additionally, semaglutide was shown to reduce the risk of major cardiovascular events by 18% and all-cause mortality by 20%. Following that data drop, Novo confirmed that it will pursue expanded approvals for Ozempic in the U.S. and Europe by the end of this year. Despite the promising results from the studies of those and other potential new CKD therapeutics so far, according to GlobalData, many kidney doctors have yet to be convinced to shake up their existing CKD treatment standards and have “mixed views” about tacking on another drug to their patients’ current regimens. “It will be easier for new drug entrants to capture CKD market share if they offer a novel mechanism of action or help to improve compliance,” Kajal Jaddoo, senior pharma analyst at GlobalData, said in the report. “Overall, nephrologists surveyed by GlobalData have indicated that the pipeline for CKD is somewhat promising, but a significant improvement in efficacy would have to be demonstrated by any therapy for it to become either a replacement or add-on to the existing therapies.”

Clinical ResultDrug ApprovalCell Therapy

21 Mar 2024

·synapse.patsnap.com

GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (2)

This article will continue to introduce the GPCR (G Protein-Coupled Receptor) targets and pipelines that garnered attention for AstraZeneca, Pfizer, and Eli Lilly at the JP Morgan Healthcare Conference 2024.For more details, please follow the link below. GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (1)GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (3)GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (4)GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (5)AstraZeneca in JPM 2024AstraZeneca, as a science-led global biopharmaceutical company, focuses on five major disease areas: oncology, rare diseases, cardiovascular/renal and metabolic diseases, respiratory and immunology, as well as vaccines and immunotherapy. In the first nine months of 2023, the company generated total revenues of $33.8 billion. The company will continue to concentrate on clinical development, advancing its leadership position in disease areas, and extensively exploring its promising, diverse product portfolio. Meanwhile, the company's business development momentum is strong, having bolstered its leading position in disease areas and its next-wave capabilities through value-adding transactions, including the acquisition of the oral GLP-1R agonist project from Eccogene. LM-305 is a monoclonal antibody ADC product targeting the GPRC5D receptor, developed by Lixian Pharmaceuticals. On May 12, 2023, LaNova Medicines announced the signing of an exclusive licensing agreement with AstraZeneca for LM-305, a pre-clinical stage antibody-drug conjugate comprising an anti-GPRC5D monoclonal antibody, a degradable protease linker, and a cytotoxic payload of MMAE. Zibotentan is an antagonist targeting the ETA receptor and is currently undergoing Phase 2 clinical development for the treatment of portal hypertension, cirrhosis, albuminuria, type 2 diabetes, chronic kidney disease, liver disease, and more. In addition, a combination product of Zibotentan and Dapagliflozin (an SGLT2 inhibitor), is undergoing Phase 3 clinical studies for chronic kidney disease, proteinuria, cirrhosis, etc. Breztri Aerosphere (Budesonide/Formoterol Fumarate/Glycopyrronium Bromide) is a combination small molecule formulation that works as a glucocorticoid receptor agonist, mAChRs antagonist, and β2AR agonist, intended for the treatment of chronic obstructive pulmonary disease (COPD). AZD9550, developed by AstraZeneca, is a dual agonist for the GCGR/GLP-1R receptors. Additionally, AZD5004 (ECC5004) is an exclusive licensed product from a collaboration between AstraZeneca and Eccogene, ECC5004 being an investigational oral once-daily GLP-1RA agonist designed for the treatment of obesity, type 2 diabetes, and other cardiac metabolic diseases. AZD5462, an original development by AstraZeneca, is a relaxin receptor RXFP1 agonist for the treatment of heart failure and is currently in Phase 1 clinical studies. Preclinical studies in monkey models with heart failure with reduced ejection fraction (HFrEF) have shown an improvement in cardiac contractility after 8 weeks of treatment, without a significant increase in mean arterial blood pressure or heart rate. AZD5462 has high selectivity for RXFP1 and lacks activity against several other closely related GPCRs. AZD6234, an original development by AstraZeneca, is a long-acting insulin receptor agonist and CALCR receptor agonist intended for clinical development in the treatment of obesity. Pfizer in JPM 2024In 2023, Pfizer provided medication and vaccine treatments to over 600 million patients worldwide. By the third quarter, the company achieved the highest revenue record among its peers. During this year, Pfizer received a record number of FDA New Molecular Entity approvals, including products such as Zavzpret, Paxlovid, Abrysvo (for OA+MI), Litfulo, Ngenla, Elrexfio, Comirnaty, Velsipity, and Penbraya. Velsipity (Etrasimod) is used for the treatment of moderate to severe ulcerative colitis. It is a selective sphingosine-1-phosphate receptor modulator S1PR1+S1PR4+S1PR5, which was added to Pfizer’s portfolio during the acquisition of Arena Pharmaceuticals in 2022. Zavzpret (zavegepant) is a CGRP receptor antagonist. Zavzpret is both the world's first and only nasal spray formulation of a calcitonin gene-related peptide (CGRP) receptor antagonist. On March 9, Pfizer’s Zavzpret entered a crowded migraine treatment market. Eli Lilly in JPM 2024Over the past six years, Eli Lilly has experienced a stock price increase of over 600%, making it the biopharmaceutical company with the highest market value in the world. Innovation serves as the foundation for sustainable performance, and obesity is the main theme for the year 2023. The company focuses on four major research areas: diabetes, obesity and cardiovascular metabolism, cancer, neurodegenerative diseases, and immunological disorders. It has made substantial investments in various therapeutic domains, such as gene therapies, to accelerate the pace of research and development. Success is never a matter of chance; it results from sustained and continuous research and development investment over an extended period of time. In the field of incretin-related therapies, the company has persevered in research and development efforts for over 30 years. External innovation is extremely important to Eli Lilly and Company, with over 50% of the company's new drug development pipeline coming from acquisitions, licensing, or collaboration. Retatrutide is a GIPR/GLP-1R/GCGR triple agonist originally developed by Eli Lilly and Company. On May 22, Eli Lilly formally submitted an application for a randomized, double-blind, phase 3 clinical study of the GIP/GLP-1/Glucagon triple agonist Retatrutide (LY3437943). The product is currently in the phase 3 clinical study stage. (Extended reading on Retatrutide: Significant: Eli Lilly will announce the phase 2 clinical trial results of the triple agonist Retatrutide (LY3437943) at ADA 2023; Eli Lilly releases clinical data on the triple agonist Retatrutide, with fierce competition in the GLP-1R agonist market!) Orforglipron (OWL833, LY3502970) is a small molecule agonist targeting GLP-1R, originally developed by Chugai. In 2018, Eli Lilly entered into a collaboration agreement with Chugai and paid a $50 million upfront payment to obtain the rights to clinically develop Orforglipron for the treatment of type 2 diabetes. (Extended reading: After Tirzepatide's approval for the treatment of obesity, how long will it be before Eli Lilly's small molecule GLP-1R agonist becomes available?) Volenrelaxin (LY3540378) is a long-acting synthetic relaxin analogue that acts as an agonist for the relaxin family peptide receptor 1 (RXFP1), developed by Eli Lilly for the treatment of chronic heart failure. It is currently in phase 2 clinical trials. LY3556050 is a small molecule SSTR4 agonist designed to modulate somatostatin signaling, affecting neuroexcitability and thus improving the regulation of inflammation and pain. It is currently undergoing phase 2 clinical development for the treatment of pain. LY3154207 (Mevidalen) is a small molecule compound that acts as a positive allosteric modulator of the dopamine receptor D1R. It is currently undergoing phase 2 clinical studies for the treatment of symptomatic leukoencephalopathy. LY3041658 (Eltrekibart) is a neutralizing chemokine that specifically blocks the activity of the CXCR1 and CXCR2 receptors. A phase 2 clinical study is currently underway for LY3041658 to treat pyoderma gangrenosum eczema. CFTX-1554 is a novel inhibitor targeting the GPCR family member Angiotensin II type 2 receptor (AT2R). CFTX-1554 was originally developed by Confo Therapeutics, and in May of the year '23, Eli Lilly reached a global licensing agreement with Confo for CFTX-1554 and other candidate compounds. CFTX-1554 is currently in phase 1 clinical studies for the development of treating neuropathic pain. Mazdutide is a synthetic peptide that acts as a GCGR+GLP-1R dual agonist, currently being developed in China in collaboration with Sinopharm for the treatment of type 2 diabetes and obesity.

20 Feb 2024

·www.biospace.com

AstraZeneca Looks to Differentiate in Kidney Disease Space Despite Setback: GlobalData

Pictured: AstraZeneca building/iStock, Sundry Photography AstraZeneca announced in its recent quarterly update that it discontinued a Phase IIb trial for its investigational drug tozorakimab for the treatment of diabetic kidney disease due to efficacy. However, a new report from analytics firm GlobalData is bullish on the potential prospects of the pharma’s pipeline drug zibotentan, if it gets approval. Despite removing tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD), zibotentan could be “an optimal treatment of choice” for patients and “of high value” for physicians trying to find treatments for the disease. “According to key opinion leaders (KOLs) interviewed by GlobalData, unmet needs in the kidney disease space include next-generation therapies with alternate mechanisms of action and enhanced clinical pro ” Kajal Jaddoo, senior pharma analyst at GlobalData, said in a statement. Tozorakimab, which acts by blocking endothelin receptors and binds to the ET-A receptor, made it to a Phase IIb DKD study in 2019, with GlobalData stating that there was evidence that increased inflammation is associated with deterioration in renal function. The trial’s hypothesis was that the drug may be “beneficial” for DKD patients on standard of care (SOC) who have inflammation as well. But that promise was not realized. “AstraZeneca has a strong commercial position and is well known in both the metabolic and cardiovascular markets. KOLs further emphasized that until further clinical data solidifies the superior or non-inferior safety and efficacy of monoclonal antibodies in combination with SOC, physicians will not substantially change their prescribing patterns,” Jaddoo said. Zibotentan acts by blocking growth receptors called endothelin receptors, binding selectively to the ET-A receptor and inhibiting endothelin-mediated mechanisms that promote cell proliferation, according to GlobalData. However, zibotentan has not seen success in other verticals, such as cancer. In 2010, zibotentan failed to improve survival in a late-phase trial in prostate cancer, while a year later a Phase III study in prostate cancer was stopped as it was unlikely to reach the endpoints of overall and progression-free survival. Still, in 2023, a combination of zibotentan and dapagliflozin showed statistically significant results in the urinary albumin-to-creatinine ratio (UACR) to asses albuminuria, with the UACR difference being down over 33% and earning a p-value of p<0.001. AstraZeneca saw a 90% plummet in its COVID-19 business in 2023 but still managed to secure 6% in total growth for the year and an 8% growth rate in the fourth quarter of last year. Areas such as cardiovascular, rare disease, oncology, and metabolism were significant growth factors for the pharma and executives are confident the company is poised for more growth in 2024. Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

Phase 2Phase 3Clinical Result

100 Deals associated with Zibotentan

External Link

KEGG	Wiki	ATC	Drug Bank
D07741	Zibotentan	-	DB06629

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 3	United States	AstraZeneca AB	04 Apr 2024
Chronic Kidney Diseases	Phase 3	China	AstraZeneca AB	04 Apr 2024
Chronic Kidney Diseases	Phase 3	Japan	AstraZeneca AB	04 Apr 2024
Chronic Kidney Diseases	Phase 3	Argentina	AstraZeneca AB	04 Apr 2024
Chronic Kidney Diseases	Phase 3	Australia	AstraZeneca AB	04 Apr 2024
Chronic Kidney Diseases	Phase 3	Austria	AstraZeneca AB	04 Apr 2024
Chronic Kidney Diseases	Phase 3	Brazil	AstraZeneca AB	04 Apr 2024
Chronic Kidney Diseases	Phase 3	Bulgaria	AstraZeneca AB	04 Apr 2024
Chronic Kidney Diseases	Phase 3	Canada	AstraZeneca AB	04 Apr 2024
Chronic Kidney Diseases	Phase 3	Denmark	AstraZeneca AB	04 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06269484 (ZEAL UNLOCK, CTgov)	Phase 2	Fibrosis \| Liver Cirrhosis \| Compensated cirrhosis	73	Zibo+Dapa (Zibo/Dapa)	rkdpaawerx = tkojlvvvio ymyqltoeam (popdqzncpx, yyacoehocd - vuaaiaxfts) View more	-	20 Jan 2026
				placebo+Zibotentan (Zibo)	rkdpaawerx = wexjfefvgr ymyqltoeam (popdqzncpx, rftuwitfvp - xnbjmnthem) View more
NCT04724837 (ZENITH-CKD, ASN2025) Manual	Phase 2	Chronic Kidney Diseases	368	Dapagliflozin 10 mg	flxeblxvfw(jyinfehzob) = ketvwlbzdn xalekggbub (iaowduahdg, -9.54， - 0.44) View more	Positive	08 Nov 2025
				Zibotentan (0.25 mg or 1.5 mg) + Dapagliflozin 10 mg	flxeblxvfw(jyinfehzob) = cxyoijwudf xalekggbub (iaowduahdg, -17.17， - 9.45) View more
NCT06087835 \| NCT04724837 (ZENITH-CKD, Pubmed \| J Am Soc Nephrol)	Not Applicable	Proteinuria \| Chronic Kidney Diseases	508	Zibotentan 0.25 mg	yqliedywvd(ivqrqjwsgc) = iknxklbjnp omoiahegbm (ohizliszxy, 0.26 - 0.45)	Positive	01 Oct 2024
				Zibotentan 1.5 mg	yqliedywvd(ivqrqjwsgc) = bpoevctvaw omoiahegbm (ohizliszxy, 0.26 - 0.45)
NCT04724837 (ZENITH-CKD, CTgov)	Phase 2	Chronic Kidney Diseases	542	Placebo+Dapagliflozin	dqzlqdxpyw(vmsvgynzkx) = hiwuqhpdhk xhvwwmfwhb (qnhfdxaeea, 1.090) View more	-	30 Jul 2024
NCT04724837 (ZENITH-CKD, ASN2023) Manual	Phase 2	Chronic Kidney Diseases	447	Zibotentan 0.25 mg+dapagliflozin 10 mg	odkoshceif(gvwiwusbyr) = ezoziewyma ekbgucuvqr (onwbeesedj, -38.4% - -13.6%) View more	Positive	03 Nov 2023
				Zibotentan 1.5 mg+dapagliflozin 10 mg	odkoshceif(gvwiwusbyr) = mlpjndptxv ekbgucuvqr (onwbeesedj, -42.5% - -23.5%) View more
NCT04724837 (ZENITH-CKD, ASN2023)	Phase 2	Chronic Kidney Diseases	447	0.25 mg/10 mg zibotentan/dapagliflozin	skhlhvlqhm(ygwdlrtrhh) = wbtevpugil rekzovxlki (ucfvdxeoyb, -38.4 to -13.6) View more	Positive	03 Nov 2023
				1.5 mg/10 mg zibotentan/dapagliflozin	skhlhvlqhm(ygwdlrtrhh) = fplpbtxnvx rekzovxlki (ucfvdxeoyb, -42.5 to -23.5) View more
NCT04724837 (ZENITH-CKD, Pubmed \| Lancet)	Phase 2	Chronic Kidney Diseases	449	Zibotentan 1.5 mg plus dapagliflozin 10 mg	xhazyzjian(vfcrfjktww) = Fluid-retention events were observed in 33 (18%) of 179 participants in the zibotentan 1.5 mg plus dapagliflozin group, eight (9%) of 91 in the zibotentan 0.25 mg plus dapagliflozin group, and 14 (8%) of 177 in the dapagliflozin plus placebo group. ubibfiphkh (fxuftsqmnd )	Positive	01 Nov 2023
				Zibotentan 0.25 mg plus dapagliflozin 10 mg
NCT00617669 (ENTHUSE M1C, ASCO_GU 12021 \| ASCO_GU 22021) Manual	Phase 3	Prostatic Cancer	466	zibotentan+docetaxel (lean)	ewjxwhlbmk(tbpjlhvjxa) = dfdyemiebn knzudnddyi (biwcfgaaor ) View more	Positive	20 Feb 2021
				zibotentan+docetaxel (overweight)	ewjxwhlbmk(tbpjlhvjxa) = qwmezyjerg knzudnddyi (biwcfgaaor ) View more
NCT02047708 (ZEBRA-1, ACR2019)	Phase 2	Chronic Kidney Diseases	16	Zibotentan 10 mg/day	ryczfukdwx(nptpvpheoi) = There were 46 reported adverse events (AE) (26 placebo and 20 active treatment) in ZEBRA-1 in 11 patients (6 placebo and 5 zibotentan). Of the 46 reported AE, 6 were serious (3 in each arm) ycshgmeyar (qussxqatel )	Positive	10 Nov 2019
				Placebo
NCT02047708 (ZEBRA-1, ASN2019)	Phase 2	Scleroderma, Systemic eGFR \| urinary MCP-1	16	Zibotentan 10 mg/day	cicscoacwx(etvwiuhuqf) = There were 46 reported adverse events (26 placebo and 20 zibotentan) with 6 serious adverse events (3 in each arm) pvkhxfvkio (giixeueuib )	Positive	05 Nov 2019
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis